SOM Biotech

SOM Biotech is a biopharmaceutical company focused on accelerating the discovery and development of therapies for orphan indications through its proprietary AI-based drug discovery technology, while forming strategic partnerships with leading research centers and pharmaceutical companies. SOM AI PRO Technology is SOM Biotech's proprietary and validated AI-based drug discovery technology. After identifying drug candidates through this technology, we successfully completed Phase 2a clinical trials for two drugs with very positive results. This will contribute to more effective treatments for two related neurodegenerative diseases, meeting high standards of safety and tolerability. One of our programs targeting TTR amyloidosis was licensed to a New York-based company after achieving positive Phase 2a results. We have three programs in the preclinical stage and an additional 20 programs in the early pipeline, all identified through this technology.